tiprankstipranks
Advertisement
Advertisement

DRUG Stock Latest News

Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K
Company AnnouncementsBright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K
18d ago
6K
DRUG
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting
PremiumCompany Announcements
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting
19d ago
6K
DRUG
Buy Rating Reiterated on Bright Minds Biosciences as BMB-101 De-Risking Progresses; $145 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on Bright Minds Biosciences as BMB-101 De-Risking Progresses; $145 Price Target Maintained
20d ago
DRUG
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options
PremiumCompany Announcements
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options
24d ago
6K
DRUG
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
PremiumThe Fly
Psychedelic: Enveric, NRx, Bright Minds report quarterly earnings
1M ago
CMND
CMPS
Bright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing
PremiumCompany AnnouncementsBright Minds Biosciences Boosts Cash Reserves as R&D Losses Widen in Q2 2026 Filing
1M ago
6K
DRUG
Bright Minds price target raised to $220 from $190 at Piper Sandler
Premium
The Fly
Bright Minds price target raised to $220 from $190 at Piper Sandler
1M ago
DRUG
Is DRUG a Buy, Before Earnings?
Premium
Pre-Earnings
Is DRUG a Buy, Before Earnings?
1M ago
DRUG
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
PremiumThe Fly
Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
2M ago
BMY
CMND
Bright Minds initiated with a Buy at Jefferies
PremiumThe Fly
Bright Minds initiated with a Buy at Jefferies
2M ago
DRUG
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
PremiumRatings
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
3M ago
DRUG
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
PremiumThe Fly
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
4M ago
PBM
ATAI
Bright Minds price target raised to $145 from $115 at H.C. Wainwright
PremiumThe FlyBright Minds price target raised to $145 from $115 at H.C. Wainwright
4M ago
DRUG
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
Premium
Ratings
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
4M ago
DRUG
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
Premium
Ratings
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
4M ago
DRUG
Bright Minds price target lowered to $126 from $142 at Baird
PremiumThe Fly
Bright Minds price target lowered to $126 from $142 at Baird
4M ago
DRUG
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
PremiumCompany Announcements
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
4M ago
6K
DRUG
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
PremiumCompany Announcements
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
5M ago
6K
DRUG
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
PremiumCompany Announcements
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
5M ago
6K
DRUG
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
PremiumThe FlyPsychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
5M ago
CMPS
DRUG
Bright Minds 1.945M share Secondary priced at $90.00
Premium
The Fly
Bright Minds 1.945M share Secondary priced at $90.00
5M ago
DRUG
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program
Premium
Company Announcements
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program
5M ago
6K
DRUG

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >